Cesare Sarrecchia

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. ncbi request reprint [Interstitial pulmonary fibrosis in chronic HCV hepatitis treated with interferon]
    C Sarrecchia
    Dipartimento di Sanita Pubblica, Universita Tor Vergata, Roma
    Recenti Prog Med 92:336-9. 2001
  2. ncbi request reprint HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
    Cesare Sarrecchia
    Universita di Roma Tor Vergata, Dipartimento di Sanita Pubblica, Rome, Italy
    J Infect Chemother 11:189-91. 2005
  3. doi request reprint Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance
    C Sarrecchia
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    Infection 39:367-70. 2011
  4. doi request reprint Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
    J Infect 67:303-12. 2013
  5. doi request reprint Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression
    Romina Salpini
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    Hepatology 61:823-33. 2015
  6. doi request reprint Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection
    Carmen Mirabelli
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
    J Infect 70:288-98. 2015
  7. doi request reprint Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy
    Laura Ceccarelli
    Infectious Disease Unit, Tor Vergata University Hospital, Rome, Italy
    J Infect 65:180-3. 2012
  8. pmc HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
    Valeria Cento
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata, Rome, Italy
    PLoS ONE 7:e39652. 2012
  9. doi request reprint Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    Dig Liver Dis 47:157-63. 2015

Collaborators

  • Mario Angelico
  • Valentina Svicher
  • Jens Verheyen
  • Loredana Sarmati
  • Claudia Alteri
  • Michela Pollicita
  • Daniele Di Paolo
  • M Andreoni
  • Lorenzo Nosotti
  • Giustino Parruti
  • Jacopo Vecchiet
  • Sergio Babudieri
  • Massimo Marignani
  • Salvatore Dimonte
  • Marco Ciotti
  • A Volpi
  • Antonio Di Biagio
  • C F Perno
  • Valeria Cento
  • Romina Salpini
  • Carmen Mirabelli
  • Ada Bertoli
  • Marianna Aragri
  • Valeria Micheli
  • Francesca Ceccherini-Silberstein
  • Matteo Surdo
  • Michela Visca
  • Guido Gubertini
  • Giuseppina Cappiello
  • Ben Berkhout
  • Nicoletta Marino
  • Sara Romano
  • Alberto Spano
  • Velia Chiara Di Maio
  • Francesco Mazzotta
  • Giuseppe Maria De Sanctis
  • Formijn Van Hemert
  • Alessandra Ricciardi
  • Laura Ceccarelli
  • Herve Fleury
  • Roberta Longo
  • Alessandro Mancon
  • Alessandra Manunta
  • Yoram Louzoun
  • Francesco De Leonardis
  • Maurizio Paoloni
  • Giuliano Rizzardini
  • Daniele Armenia
  • Chiara D'Amore
  • Christina Becker
  • Laura Ambra Nicolini
  • Mariarosaria Esposito
  • Aldo Marrone
  • Pascal Trimoulet
  • Zhichao Lian
  • Simona Landonio
  • Fabiola Di Santo
  • Luna Colagrossi
  • Claudio Maria Mastroianni
  • Maria Concetta Bellocchi
  • Maria Stella Mura
  • Gloria Taliani
  • Adriano Gasbarrini
  • Adriano Pellicelli
  • Miriam Lichtner
  • Domenico Di Carlo
  • Francesco Paolo Antonucci
  • Martina Bernassola
  • Massimo Siciliano
  • Maria Mercedes Santoro
  • Carlo Federico Magni
  • Ilaria Lenci
  • Luca Carioti
  • Maria Francesca Cortese
  • Monica Tontodonati
  • Jing Maria Zhang
  • Maria Neumann-Fraune
  • Fabio Mercurio
  • Lucia Parrotta
  • Pasquale Sordillo
  • Stefano Alcaro
  • Anna Artese
  • Giosuè Costa

Detail Information

Publications9

  1. ncbi request reprint [Interstitial pulmonary fibrosis in chronic HCV hepatitis treated with interferon]
    C Sarrecchia
    Dipartimento di Sanita Pubblica, Universita Tor Vergata, Roma
    Recenti Prog Med 92:336-9. 2001
    ..The correlation among interstitial pulmonary fibrosis, HCV infection and interferon treatment is discussed; however in the described case, the pulmonary pathology was correlated to interferon treatment...
  2. ncbi request reprint HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
    Cesare Sarrecchia
    Universita di Roma Tor Vergata, Dipartimento di Sanita Pubblica, Rome, Italy
    J Infect Chemother 11:189-91. 2005
    ....
  3. doi request reprint Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance
    C Sarrecchia
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    Infection 39:367-70. 2011
    ....
  4. doi request reprint Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
    J Infect 67:303-12. 2013
    ..Furthermore, due to HBV-RT/HBsAg gene-overlap, they can have an impact on HBsAg-detection and quantification...
  5. doi request reprint Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression
    Romina Salpini
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    Hepatology 61:823-33. 2015
    ..1% of HBV-reactivated patients (vs. 0% of chronic patients; P<0.001); 5 of 7 patients carrying these sites remained HBsAg negative despite HBV reactivation. NLG can mask immunogenic epitopes, abrogating HBsAg recognition by Abs...
  6. doi request reprint Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection
    Carmen Mirabelli
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
    J Infect 70:288-98. 2015
    ..To define HBsAg-mutations correlated with different serum HBV-DNA levels in HBV chronically-infected drug-naive patients...
  7. doi request reprint Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy
    Laura Ceccarelli
    Infectious Disease Unit, Tor Vergata University Hospital, Rome, Italy
    J Infect 65:180-3. 2012
    ..Furthermore, it is of outstanding importance to identify alternative markers (e.g. cccDNA, HBV core related antigen, etc.), that could be predictive of HBV reactivation...
  8. pmc HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
    Valeria Cento
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata, Rome, Italy
    PLoS ONE 7:e39652. 2012
    ..Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific HCV-genotypes are differently prone to develop resistance to linear and macrocyclic protease-inhibitors (PIs)...
  9. doi request reprint Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    Dig Liver Dis 47:157-63. 2015
    ..Triple therapy with telaprevir/boceprevir + pegylated-interferon+ribavirin can achieve excellent antiviral efficacy, but it can be burdened with resistance development at failure...